Chronic Granulomatous Disease
Also known as: CGD, Quie Syndrome, Chronic Granulomatous Disorder
Chronic Granulomatous Disease (CGD) is a group of hereditary diseases in which certain cells of the immune system have difficulty forming reactive oxygen compounds used to kill ingested pathogens. This leads to the formation of granulomas in various organs and increased susceptibility to bacterial and fungal infections.
Imagine your body's soldiers (immune cells) have trouble making the right weapons to fight off bad germs. This makes you get sick more often, and your body might form lumps (granulomas) trying to contain the germs. Doctors can give you medicine to help prevent infections and sometimes even fix the problem with a special transplant.
Signs & Symptoms
- Recurrent bacterial and fungal infections
- Granuloma formation in various organs (lungs, liver, spleen, lymph nodes)
- Pneumonia
- Abscesses
- Lymphadenitis
- Gastrointestinal inflammation
- Delayed growth
- Anemia
Treatment Options
Prophylactic Antibiotics
HIGHLY EFFECTIVEProphylactic Antifungals
HIGHLY EFFECTIVEInterferon Gamma
MODERATELY EFFECTIVE Approved 1990Granulocyte Colony-Stimulating Factor (G-CSF)
MODERATELY EFFECTIVEHematopoietic Stem Cell Transplantation (HSCT)
HIGHLY EFFECTIVEGene Therapy
EXPERIMENTALSurgery (for abscess drainage)
SUPPORTIVECorticosteroids
MODERATELY EFFECTIVEDiagnosis
- Neutrophil function tests (e.g., DHR assay)
- Genetic testing
- Blood tests (CBC, inflammatory markers)
- Imaging studies (X-rays, CT scans) to detect infections and granulomas
History
CGD was first described in the 1950s as a fatal disease of childhood characterized by recurrent infections and granuloma formation. The underlying defect in neutrophil function was identified in the 1960s, and the genetic basis of the disease was elucidated in subsequent decades.
Recent Breakthroughs
Gene Therapy Shows Promise in CGD
Early clinical trials of gene therapy for X-linked CGD have demonstrated promising results, with some patients achieving long-term correction of their neutrophil function and reduced infection rates.
Improved HSCT Outcomes for CGD
Advances in hematopoietic stem cell transplantation (HSCT) techniques, including reduced-intensity conditioning regimens and improved donor matching, have led to better outcomes for patients with CGD undergoing HSCT.